A recent study published in the Journal of Psychopharmacology indicates that during high-dose psilocybin treatment sessions for post-traumatic stress disorder, participants and support staff spend the vast majority of their time in silence. The research suggests that the support provided during these sessions relies primarily on quiet, unobtrusive presence rather than active talk therapy. This offers an updated perspective on how the clinical administration of psychedelic compounds actually functions.
Psilocybin is a psychoactive compound found in certain species of “magic” mushrooms. In recent years, it has gained attention as a potential medical treatment for various mental health conditions, including post-traumatic stress disorder, commonly known as PTSD. PTSD is a mental health condition triggered by experiencing or witnessing a terrifying event, often leading to severe anxiety, flashbacks, and uncontrollable thoughts. In clinical trials, psilocybin is typically administered in a controlled setting with trained support staff present to ensure safety.
A common misconception is that patients undergo traditional talk therapy while actively under the influence of the drug. This idea partly stems from the structure of other experimental treatments, such as trials involving MDMA, which often feature active, verbal psychotherapy during the drug session. Because high doses of psilocybin induce intense, internally focused altered states of consciousness, carrying on a regular therapeutic conversation is often impractical.
“There was a general misunderstanding around the term ‘psychedelic assisted psychotherapy’. It implies that a psychedelic drug is administered to boost a form of psychotherapy, which most people understand as verbal to and fro between a patient and a therapist,” said Guy M. Goodwin, chief medical officer at Compass Pathways and emeritus professor of psychiatry at the University of Oxford.
Goodwin added, “In fact, as our paper shows, the vast majority of the time there is silence when a patient has taken a 25mg dose of COMP360 psilocybin. There is no psychotherapy going on. So, it makes more sense to call this a ‘psychedelic treatment’, which clearly places the emphasis on the drug’s effect.”
To explore these interactions, the scientists analyzed data from an open-label clinical trial involving 22 adult participants. All the participants had been diagnosed with PTSD and had a baseline score on a standard diagnostic scale indicating moderate to severe symptoms. Each person received a single 25-milligram dose of a synthetic psilocybin formulation known as COMP360.
The clinical outcomes for these participants provided important context for understanding the treatment’s impact. “This particular study was in patients with PTSD. Most of the patients experienced a clinically significant reduction in symptoms after a single 25mg dose of COMP360 psilocybin,” Goodwin noted. “Most described the treatment as preferable to either the drug or psychotherapy they had previously received.”
The rapid onset of these improvements stood out to the researchers. When asked about unexpected findings, Goodwin highlighted “[t]he immediacy of the therapeutic benefit, which had not been seen before for PTSD.”
The treatment process involved three distinct phases. First, participants attended three preparation sessions with two trained support providers. Next came the administration session, which lasted six to eight hours, during which participants lay in a dimly lit room, wore eyeshades, and listened to a standardized music playlist. Finally, participants attended three follow-up sessions to discuss their experiences.
The researchers recorded audio from all the sessions and transcribed the conversations. They then calculated the speech rate, measured in words per minute, for both the participants and the support providers. When analyzing the data, the authors controlled for the fact that each participant had multiple sessions and that some participants shared the same support providers. This mathematical control helped ensure the models accurately reflected the underlying speech patterns without falsely inflating the confidence of the estimates.
In addition to calculating word counts, the researchers conducted in-depth interviews with the participants the day after the administration session. These interviews provided qualitative data about how the participants felt regarding the support they received. The researchers also asked participants to complete a questionnaire measuring the intensity of their altered state of consciousness at the end of the psilocybin session.
The analysis of the audio transcripts showed a stark contrast in speech rates between the different phases of the trial. During the psilocybin administration sessions, an average of 78 percent of the time passed without any talking. In comparison, silence accounted for only 25 to 30 percent of the total time during the preparation and follow-up sessions.
During the preparation phase, the words spoken per minute were generally balanced between the participants and the support staff. In the follow-up sessions, the participants spoke at a much higher rate than the providers. During the administration session itself, the speech rates for both groups dropped to very low levels. The talking that did occur mostly took place at the very beginning and the very end of the six-to-eight-hour window.
The researchers also found a negative correlation between the intensity of the psychedelic experience and the amount of talking. Participants who reported more intense feelings of boundlessness and ego dissolution tended to speak even fewer words per minute. This suggests that more immersive drug effects naturally limit the capacity or desire for verbal communication.
The post-session interviews provided evidence that participants appreciated the quiet approach of the staff. Many individuals reported that the support was unobtrusive but highly impactful. The quiet presence of the staff allowed participants the freedom to focus inwardly and autonomously navigate their own thoughts.
This internal focus is central to how the authors view the treatment’s mechanisms and future applications. Goodwin explained the team’s hope “that psychedelic treatment will be available for depressed patients who have not responded to conventional treatments next year and that it involves an inwardly directed intrapersonal experience, not psychotherapy.”
When participants did need support, it typically took the form of brief reassurance or validation. This included a staff member briefly holding a participant’s hand or offering a short verbal reminder of their physical location. Participants indicated that these small gestures provided an anchor of safety during periods of emotional intensity.
A small sample size is a primary limitation of this study, as it only included 22 individuals. The trial was also open-label, meaning both the researchers and the participants knew they were receiving psilocybin. Additionally, the measure of words per minute is a relatively simple metric for capturing the complexity of human language and clinical interaction.
A lack of conversation during therapy might outwardly resemble an absence of emotional support. However, the interview data suggests the quiet presence of staff members actively provided a strong sense of safety. The findings do not imply that verbal engagement is unimportant in mental health treatment as a whole. Instead, the research indicates that high-dose psilocybin sessions function differently than conventional talk therapy, relying on passive monitoring rather than active dialogue.
Future research could expand on these findings by studying larger groups of patients undergoing psychedelic treatments. Scientists might use natural language processing software to analyze the emotional tone and semantic content of the speech during these sessions.
The authors are already looking ahead to broader applications of their work. “We are in the process of submitting data to FDA in pursuit of an approval for the treatment of difficult to treat depression with COMP360 psilocybin. We are also starting a major late-stage study in PTSD,” Goodwin stated. He concluded, “We are not surprised by the findings of this study and we are very proud of COMP360’s differentiated clinical profile that has the potential to help the many millions of patients in need of new and effective options.”
The study, “Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder,” was authored by Robert F. Dougherty, Nadav Liam Modlin, Niall M. McGowan, Patrick Staples, Ella Williams, Patrick Clarke, Mario Shafiei, Carly Leininger, Merve Alti, Megan Croal, Lindsey Marwood, Namik Kirlić, Gregory A. Ryslik, and Guy M. Goodwin.
Leave a comment
You must be logged in to post a comment.